research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-02 and is reviewed periodically as new material appears.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
=== EC 1.12.99 With unknown physiological acceptors === EC 1.12.99.1: Now EC 1.12.98.1, coenzyme F420 hydrogenase EC 1.12.99.2: Now shown to be two enzymes, EC 1.12.98.3, Methanosarcina-phenazine hydrogenase and EC 1.8.98.1, CoB—CoM heterodisulfide reductase EC 1.12.99.3: Now EC 1.12.5.1, hydrogen:quinone oxidoreductase EC 1.12.99.4: Now EC 1.12.98.2, 5,10-methenyltetrahydromethanopterin hydrogenase EC 1.12.99.5: Identical to EC 1.13.11.47, 3-hydroxy-4-oxoquinoline 2,4-dioxygenase EC 1.12.99.6: hydrogenase (acceptor)
Anxiety disorders Bobble-head doll syndrome – a sensation that the skull may fall off the cervical spine Clumsiness and motor delay Cognitive and memory decline Double or blurred vision Dysphagia – a sensation of choking Dyspnea Fatigue Lhermitte's sign Migraine Nausea Neck, shoulder, and jaw pain Occipital headaches Orthostatic intolerance Photophobia Syncope Tenderness at base of skull Tinnitus Tremors Palpitations Vertigo or dizziness Weakness of limbs Symptoms are frequently worsened by a Valsalva maneuver or by being upright for long periods of time. Being upright is problematic because gravity allows increased interaction between the brain stem and the top of the spinal column, increasing symptoms. Lying in the supine position can bring short-term relief. Lying supine eliminates the downward gravitational pull, reducing symptoms to some degree. Lying with the feet somewhat higher and head lower can be helpful in symptom reduction.
== Signs and symptoms == Generally, the majority of individuals with creatine transporter defect express the following symptoms with varying levels of severity: developmental delay and regression, intellectual disability, and abnormalities in expressive and cognitive speech. However, several studies have shown a wider variety of symptoms including, but not limited to attention deficit and hyperactivity with impulsivity, myopathy, hypotonia, semantic-pragmatic language disorder, oral dyspraxia, extrapyramidal movement disorder, constipation, absent speech development, seizures, and epilepsy. Furthermore, symptoms can significantly vary between hemizygous males and heterozygous females, although, symptoms are generally more severe in hemizygous males. Hemizygous males more commonly express seizures, growth deficiency, severe intellectual disability, and severe expressive language impairment. Heterozygous females more commonly express mild intellectual disability, impairments to confrontational naming and verbal memory, and learning and behavior problems.
=== Sexual === Isotretinoin is also associated with permanent sexual side effects, namely erectile dysfunction and reduced libido. In October 2017, the UK MHRA issued a Drug Safety Update to physicians in response to reports of these problems. This was in response to an EU review, published in August 2017, which states that a plausible physiological explanation of these side effects "may be a reduction in plasma testosterone". The review also stated that "the product information should be updated to include 'sexual dysfunction including erectile dysfunction and decreased libido' as an undesirable effect with an unknown frequency". There have also been reports of spermatogenesis disorders, such as oligospermia. 27 cases of sexual dysfunction report either negative dechallenge or positive dechallenge.
Sources: en.wikipedia.org
== The Creation and History of Venomics Techniques == Venom is made up of multiple proteinous components, with each component differing in its structural complexity. Venom can be a mixture of simplistic peptides, secondary (α-helices and β-sheets) structured proteins and tertiary structured proteins (crystalline structures). Furthermore, depending on the organism, there can be fundamental differences in the strategies they incorporate in their venom contents, the biggest difference being between invertebrates and vertebrates. For example, the majority of funnel-web spider's venom was made up of peptides between 3-5 KDa (75%), with the remaining peptides being between 6.5 and 8.5 KDa in mass. Conversely, snake venom is made up of more complex protein such as modified saliva proteins (CRISPs & kallikrein) and protein families that have had their genes recruited from other tissue groups (Acetylcholinesterase, crotasin, defensin & cystatin). Due to this extraordinary amount of variation in the components that make up venom, a new field was needed to identify and categorise the millions of bioactive molecules that are found within the venom. Therefore, by combining the methods of multiple fields such as genomics, transcriptomics, proteomics and bioinformatics, an aptly named new field emerged named venomics. Venomics was first established in the latter half of the 20th century as different ‘-omic’ technologies began to rise in popularity. However, the progression of venomics since its inception has always been reliant on and limited by the advancement of technology.
=== Redox buffer in the irradiated fuel matrix === Molybdenum behaves as a redox buffer in the spent nuclear fuel matrix. 99Mo is one of the most abundant fission product, with a fission yield of 6.1% close to that of xenon (135Xe, 6.33%). Molybdenum plays a critical role in nuclear fuel chemistry because it affects the fuel's oxygen fugacity. Molybdenum produced by nuclear fission in the fuel matrix inhibits the oxidation of the uranium dioxide.
Class I has two highly conserved sequence motifs. It aminoacylates at the 2'-OH of a terminal adenosine nucleotide on tRNA, and it is usually monomeric or dimeric (one or two subunits, respectively). Class II has three highly conserved sequence motifs. It aminoacylates at the 3'-OH of a terminal adenosine on tRNA, and is usually dimeric or tetrameric (two or four subunits, respectively). Although phenylalanine-tRNA synthetase is class II, it aminoacylates at the 2'-OH. The amino acids are attached to the hydroxyl (-OH) group of the adenosine via the carboxyl (-COOH) group. Regardless of where the aminoacyl is initially attached to the nucleotide, the 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification. Bacterial aminoacyl-tRNA synthetases can be grouped as follows:
Sources: en.wikipedia.org
=== Tolerance === Unlike with other classical psychedelics, tolerance does not seem to develop to the subjective effects of DMT. Studies report that DMT did not exhibit tolerance upon repeated administration of twice a day sessions, separated by 5 hours, for 5 consecutive days; field reports suggests a refractory period of only 15 to 30 minutes, while the plasma levels of DMT was nearly undetectable 30 minutes after intravenous administration. Another study of four closely spaced DMT infusion sessions with 30 minute intervals also suggests no tolerance buildup to the psychological effects of the compound, while heart rate responses and neuroendocrine effects were diminished with repeated administration. Similarly to DMT by itself, tolerance does not appear to develop to ayahuasca. A fully hallucinogenic dose of DMT did not demonstrate cross-tolerance to human subjects who are highly tolerant to LSD; hence, research suggests that DMT exhibits unique pharmacological properties compared to other classical psychedelics. Contrary to earlier findings however, subsequent clinical studies employing DMT by continuous intravenous infusion (also known as DMTx) have found rapid and moderate acute tolerance development with DMT.
Narrated by Stephen Rashbrook, produced by Nick Catliff, directed by Henry Singer, made by Lion Television and Sandpaper Films. Shown on Monday 7 February 2000 on The Nature of Things in Canada 27 September Near Miss, about ATC, the 1960 New York mid-air collision in December 1960; around 7,500 aircraft visit the three airports each day; LaGuardia Airport has two conjoined runways that operate in a strange mixed way; on 3 April 1998 there was a near miss; USAir Flight 5050 in September 1989; Colombian Avianca Flight 52 in January 1990 approached John F. Kennedy International Airport when running out of fuel, when a 4-hour flight turned into 6 hours due to weather. Narrated by Jack Davenport, directed by Jeremy Llewellyn-Jones, produced by Emma Bowman, made by Windfall Films and The Learning Channel (TLC). On All 4 4 October Curing the Incurable, the strange teratoma cells; Paul R. Sanberg of the University of South Florida; Irving Weissman of Stanford University; pathologist John Goepel; Peter Andrews (biologist); neurosurgeon Douglas Kondziolka of the University of Pittsburgh Medical Center, and stereotactic surgery; John Sinden of ReNeuron; Ann Tsukamoto of CytoTherapeutics. Narrated by David Malone, made by Boa Picture Company 20 December Talking with Aliens, an Equinox Special, with zoologist Denise L. Herzing, made by Pioneer Films
=== Research articles === Ifa, Demian R; Eberlin, Livia S (January 1, 2016), "Ambient Ionization Mass Spectrometry for Cancer Diagnosis and Surgical Margin Evaluation", Clinical Chemistry, 62 (1), Oxford University Press (OUP): 111–123, doi:10.1373/clinchem.2014.237172, ISSN 0009-9147, PMC 5315420, PMID 26555455 Sans, Marta; Gharpure, Kshipra; Tibshirani, Robert; Zhang, Jialing; Liang, Li; Liu, Jinsong; Young, Jonathan H.; Dood, Robert L.; Sood, Anil K.; Eberlin, Livia S. (May 31, 2017), "Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging", Cancer Research, 77 (11), American Association for Cancer Research (AACR): 2903–2913, doi:10.1158/0008-5472.can-16-3044, ISSN 0008-5472, PMC 5750373, PMID 28416487 Santagata, Sandro; Eberlin, Livia S.; Norton, Isaiah; Calligaris, David; Feldman, Daniel R.; Ide, Jennifer L.; Liu, Xiaohui; Wiley, Joshua S.; Vestal, Matthew L.; Ramkissoon, Shakti H.; Orringer, Daniel A.; Gill, Kristen K.; Dunn, Ian F.; Dias-Santagata, Dora; Ligon, Keith L.; Jolesz, Ferenc A.; Golby, Alexandra J.; Cooks, R. Graham; Agar, Nathalie Y. R. (June 30, 2014), "Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery", Proceedings of the National Academy of Sciences, 111 (30): 11121–11126, Bibcode:2014PNAS..11111121S, doi:10.1073/pnas.1404724111, ISSN 0027-8424, PMC 4121790, PMID 24982150 Correa, Deleon N.; Santos, Jandyson M.; Eberlin, Livia S.; Eberlin, Marcos N.; Teunissen, Sebastiaan F.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.